Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Accumulated Expenses for 14 consecutive years, with $194.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 12.13% year-over-year to $194.0 million; the TTM figure through Mar 2026 stood at $194.0 million (up 12.13% YoY), while the FY2025 annual figure was $89.0 million, down 63.07% from the prior year.
• Accumulated Expenses rose to $194.0 million in Q1 2026 per RARE's latest filing, from $89.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $241.0 million in Q4 2024 and bottomed at $47.9 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $129.8 million across 5 years, with a median of $126.4 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 167.28% — and 2025, when it plunged 63.07%.
• Ultragenyx Pharmaceutical's Accumulated Expenses stood at $78.9 million in 2022, then surged by 148.91% to $196.5 million in 2023, then rose by 22.66% to $241.0 million in 2024, then slumped by 63.07% to $89.0 million in 2025, then jumped by 117.98% to $194.0 million in 2026.
• Business Quant data shows RARE's Accumulated Expenses at $194.0 million in Q1 2026, $89.0 million in Q4 2025, and $220.5 million in Q3 2025.